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Introduction: Complicated pleural effusions are difficult to manage
with conventional strategies. In this study, we review the safety,
efficacy, and durability of PleurX catheters (Denver Biomedical,
Golden, CO) for managing complicated pleural effusions and de-
scribe a patient population who might benefit.
Patients and Methods: From July 1999 to February 2003, 63
PleurX catheters were placed in 58 symptomatic patients (an addi-
tional five had bilateral catheters) to manage complicated pleural
effusions. Patients selected for catheter placement tended to have
poor performance status (Eastern Cooperative Oncology Group 2)
or had failed standard therapies. Of the 63 catheters, 52 (83%) were
placed because of malignant complicated pleural effusions. A reg-
istry of patients was constructed, and data were obtained from
review of medical records. Nonparametric estimates of freedom
from reintervention and overall survival were obtained by the
Kaplan-Meier method.
Results: Catheter-related complications were noted in four of 58
patients (7%) and included one each of pneumothorax, seroma,
empyema, and pain syndrome. Freedom from reintervention for
effusion management was 95%. Of the patients, 86% (50 of 58)
experienced dyspnea relief. There were no procedure-related mor-
talities. Catheters remained functional up to 330 days, and four of 63
(6%) required one-time thrombolysis with tissue plasminogen acti-
vator.
Conclusions: PleurX catheters are safe, effective, and durable
solutions for complicated pleural effusions and seem to provide an
attractive alternative for patients who have few other palliative
options. We consider the catheters as first-line therapy for these
patients.
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Pleural effusions represent the most common referral forthe general thoracic surgeon. Most effusions require little
more than diagnostic thoracentesis. Pleural scarification, with
or without thoracoscopy, is generally reserved for recurrent,
symptomatic, malignant pleural effusion (MPE).1,2 A
smaller cohort of patients will present with complicated
pleural effusions (CPE) that are seldom amenable to stan-
dard therapies.3,4 High-volume pleural effusions, intracta-
ble effusions in severely debilitated patients, and those
presenting with entrapped lung syndrome comprise the
spectrum of this disease. Benign and malignant disease
processes contribute to CPE.
Alternative treatment approaches are required to man-
age patients with CPE. To this end, a recently developed
pleurocutaneous catheter (PleurX; Denver Biomedical,
Golden, CO) seems promising. The purposes of this study
were to (1) assess our indications; (2) evaluate the safety; (3)
determine the efficacy; and (4) examine durability of the
PleurX catheter for CPE.
PATIENTS AND METHODS
Patients
Between July 1999 and February 2003, 63 PleurX
catheters were placed in 58 symptomatic patients (an addi-
tional five patients had staged bilateral catheter placement). A
registry of patients was constructed, data were obtained from
review of medical records, and a retrospective review of
catheter use was undertaken. The Institutional Review Board
approved the study.
Use of PleurX catheters was restricted to selected
patients. Patients with MPE were generally treated with
drainage and pleurodesis. It became apparent that this strat-
egy was not universally applicable, however. In particular,
patients with entrapped lung, high-volume effusions, or prior
failed pleurodesis often benefited from drainage, although no
permanent solution was available. Moreover, patients with
decreased performance status or decreased life expectancy
had limited cost-effective palliative solutions. Based on the
surgeons’ and medical oncologists’ judgment, these patients
were offered pleurocutaneous drainage as palliation. Summa-
ries of effusion etiologies (Table 1) and patient descriptors
(Table 2) have been provided. An assessment of clinical
conditions for which catheters were used is summarized in
Figure 1. Of 63 catheters, 52 (83%) were placed because of
malignant CPE, and hospitalized patients comprised 92% of
the group.
Technique
Early in the series, catheters were placed as previously
described.2 An open technique was adopted after 17 catheters
were placed because of dissatisfaction with the recommended
Seldinger technique. After identification of appropriate can-
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic,
Cleveland, Ohio.
This original work was presented in abstract form at the 10th World
Conference on Lung Cancer (IASLC), August 10-14, 2003, Vancouver,
British Columbia, Canada.
Address correspondence to: Sudish C. Murthy, MD, PhD, Department of
Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid
Ave., Desk F24, Cleveland, OH 44195. E-mail: Murthys1@ccf.org
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0107-0697
Journal of Thoracic Oncology • Volume 1, Number 7, September 2006 697
didates, chest radiograph, computed tomography, or ultra-
sound was used to accurately locate the effusion. Most
patients (78%) were transported into a procedure room,
consciously sedated, and placed in a lateral decubitus position
(effusion side up). Sterile technique was used to prepare the
entire hemithorax. Topical 1% lidocaine-HCl was instilled
over interspace 7 (approximately) in the posterior axillary
line (unless directed elsewhere by preoperative studies), and
a small (1-cm) thoracostomy incision was made. The cathe-
ter, tunneled subcutaneously from a more anterior and infe-
rior location, was then passed into the hemithorax through the
thoracostomy incision. The thoracostomy was closed with
interrupted nylon sutures. Catheters were immediately ac-
cessed on completion of the procedure. Of the 63 catheters,
14 (22%) were placed during general anesthesia because
unsuspected entrapped lung syndrome was found during a
planned thoracoscopy.
Outcomes
An assessment of postoperative relief of dyspnea was
available for all patients (improved, no change, worse). Pa-
tients were questioned immediately after the procedure and
on the following day by the surgeon, unless the patient was
discharged. (This information was recorded in the medical
record.) Patients were followed twice weekly for the first 2
weeks, then monthly until catheters were removed or death.
In addition, postoperative complications (catheter infection,
seroma or incisional drainage, catheter-related empyema,
catheter-related pain, pneumothorax, hemothorax) were doc-
umented. Length of hospitalization pre- and post-catheter
insertion was recorded. Durability was assessed by duration
of catheter placement (until removed or patient death) and
continued function of the catheter. Freedom from reinterven-
tion was noted for patients who, aside from thrombolysis of
the catheter, received no additional procedure to palliate their
presenting effusion.
Data Analysis
For the analysis, patients were followed cross-section-
ally on February 2003. Mean follow-up was 71 days (range,
4 to 400 days). Categorical variables were summarized by
frequencies and percentages. Statistical analyses included 2,
Fisher’s exact, and Student’s t tests and were facilitated by
SPSS. Nonparametric estimates of freedom from reinterven-
tion and overall survival were obtained by the Kaplan-Meier
method.
RESULTS
Safety
There were no procedure-related mortalities, and four
patients experienced a postoperative morbidity. Complica-
tions included one each of pneumothorax, seroma, empyema,
and catheter-related pain. The pneumothorax was managed
by connecting the PleurX to a water-seal system; the air leak
resolved within 3 days. The seroma required a compressive
FIGURE 2. Freedom from reintervention.
FIGURE 1. Assessment of patients who received catheters.
TABLE 2. Patient Characteristics
Median age (years) 60.7
Male 27/58 (47%)
ECOG status
0 0 (0%)
1 16 (28%)
2 26 (45%)
3 13 (22%)
4 3 (5%)
ECOG, Eastern Cooperative Oncology Group.
TABLE 1. Disease Process Causing Pleural Effusion
Malignant 83%
NSCLC 19
Metastatic disease 19
Lymphoma 3
Small cell 3
Other malignant 8
Benign 17%
CHF 3
Hepatic cirrhosis 2
Other benign 6
n  63. CHF, congestive heart failure; NSCLC, non-small cell lung cancer.
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dressing and daily catheter drainage to keep the hemithorax
empty for 2 weeks. An empyema (klebsiella) developed after
3 months of frequent catheter use in a young woman with
malignant mesothelioma. The empyema was accompanied by
klebsiella pneumonia of the ipsilateral lung and was managed
conservatively by thrombolytic therapy and continued drain-
age. The patient died while in hospice care 2 weeks after the
diagnosis of empyema. One patient required early catheter
removal because of intractable pain during drainages.
Efficacy
Fifty patients (86%) reported an improvement in respi-
ratory symptoms. Freedom from reintervention was 95%
(Figure 2). We did not include instances (6%) in which
thrombolysis (10 mg TPA) was required to restore catheter
patency. Thrombolysis was performed in the outpatient
clinic, required 1 hour, and was successful in all cases.
Durability
Duration of catheter placement ranged from 5 to 330
days. Aside from catheter thrombosis discussed in Efficacy,
no catheter required manipulation or replacement because of
dysfunction. Most catheters were accessed once or twice
weekly, although two patients required daily drainage.
DISCUSSION
Patients with CPE present a difficult clinical challenge.
Standard therapies such as repeated thoracentesis or chemical
pleurodesis1,2 frequently fail, and more innovative approaches
must be considered. The goal of therapy for malignant CPE is
effective palliation, as most patients have disseminated malig-
nancy and a subsequently short life expectancy. Consequently,
the solution in these patients should be simple, reproducible, and
durable.
Current strategies to control CPE include pleuroperito-
neal shunting or transcutaneous pleural drainage catheters. To
this end, a 15-year experience with pleuroperitoneal shunts
has recently been published.4 More than 50% of the shunts in
this series of patients were placed to salvage failed conven-
tional therapies. The authors reported a 2% mortality and
15% complication rate. All procedures were conducted under
general anesthesia through video-assisted thoracic surgery or
mini-thoracotomy. Although this approach has proven to be
effective,4,5 several technical difficulties exist. Because the
chamber capacity of the shunt is only 1.5 cc, numerous
manual pumps are required to evacuate even moderate vol-
ume effusions. This frequently leads to inflammation and
tenderness of the pump pocket and subsequent non-compli-
ance.6 Additionally, the small size of both the pump chamber
and catheter can lead to early occlusion by proteinaceous
debris, necessitating replacement. An external pleuroperito-
neal shunt seems to circumvent some of these problems.6
A more promising treatment of CPE is intermittent
drainage by permanent, indwelling, percutaneous catheters.
Although several types of catheters have been examined,7–9
we focused on the PleurX catheter, as randomized data
suggested equivalence to chemical pleurodesis for MPE.10 In
this study, the two treatment groups were equal when dis-
ability scores and dyspnea were the measured outcomes.
We designed this study to evaluate the use of the
PleurX catheter for CPE. Our current practice favors the use
of operative pleurodesis (with dry talcum) for good perfor-
mance-status patients with uncomplicated MPEs. Because
this approach is successful for more than 90% of these
patients,1 we believe that, unless future data suggest other-
wise, operative pleurodesis is the gold standard. Moreover,
because we are unsure of the consequences of protracted
chest drainage on the overall survival and fitness of patients
with cancer, we avoid catheter placement for uncomplicated
effusions.
We found that PleurX catheters performed exception-
ally well for CPE. The 95% freedom-from-intervention rate
for CPE compares favorably with talcum pleurodesis for
uncomplicated effusions. Moreover, the low complication
rate, excellent durability, and patient comfort (only one pa-
tient complained of significant pain) help to fulfill the criteria
needed for a palliative care instrument.
FIGURE 3. Plain chest radiogram pre- and post-evacuation
of a malignant pleural effusion and placement of PleurX
catheter (Denver Biomedical, Golden, CO). The image after
catheter insertion demonstrates a densely entrapped lung.
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We modified the placement technique from that recom-
mended by the manufacturer in that we use an open technique
rather than the closed Seldinger technique. With the patient
placed in a decubitus position (effusion side up), the lung is
buoyed up to the lateral chest wall (unless fluoroscopy is
used) and can easily be punctured during closed placement. A
thoracostomy incision allows the operator to direct catheter
placement and reduces the risk of pneumothorax. A disad-
vantage of the open technique is that a larger access site
might foster postoperative seroma (reflux of effusion) along
the catheter tract. We avoid this problem by accessing the
pleural space higher (more cephalad) on the chest cavity and
have patients drain themselves every other day for 7 to 10
days to allow for sealing of the thoracostomy site.
Although our experience is limited, we have begun
using these catheters for benign CPE. Surprisingly, aninition
has not been a problem, and of 15 catheters placed for benign
CPE, six have been removed with lasting control of the
effusion. We do not routinely place catheters in patients
receiving anticoagulation therapy (heparin or warfarin) be-
cause of concerns for iatrogenic hemothorax from suction
trauma.
Regardless of etiology, the care of patients with en-
trapped lung syndrome is particularly difficult to manage
(Figure 3). Initially, it is important to determine whether
evacuation of the pleural space improves respiratory function.
Consequently, effusions should be thoracentesed before fur-
ther treatment plans. Loculated effusions are ultrasound-
marked to allow for safer access. It is unclear why some
patients benefit from drainage. We speculate that ipsilateral
chest drainage improves compliance of the contralateral lung
by two mechanisms. First, the mediastinum is relaxed. Sec-
ond, the ipsilateral diaphragm is elevated, which reduces
intra-abdominal pressure and eases breathing. Use of the
PleurX catheter for these patients has proven particularly
rewarding, and, surprisingly, 48% of catheters placed for
entrapped lung have been able to be removed. Protracted
catheter use eventually causes organization of the pleural
process with some condensation of the cavity. We reserve
operative decortication for malignant entrapped lung syn-
drome secondary to mesothelioma. Patients, however, must
demonstrate good performance status; otherwise, they are
relegated to catheter placement. We have not compared this
pleurocutaneous drainage system with any other, such as
placement of pigtail catheters and thrombolysis. This is, in
part, because the PleurX catheter is tunneled, which permits
long-term use.
CONCLUSION
The PleurX catheter offers promise as a tool for man-
aging CPE. Its ease of placement, patient acceptance, and
durability are attractive features. Future randomized trials and
cost analyses will further define its role for use in uncompli-
cated recurrent effusions.
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